PCVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PCVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Vaxcyte's average basic shares outstanding for the quarter that ended in Mar. 2024 was 111.69 Mil.
The historical data trend for Vaxcyte's Shares Outstanding (Basic Average) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaxcyte Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Shares Outstanding (Basic Average) | Get a 7-Day Free Trial | 25.60 | 29.55 | 51.92 | 64.88 | 97.16 |
Vaxcyte Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Shares Outstanding (Basic Average) | Get a 7-Day Free Trial | 86.21 | 98.06 | 63.54 | 95.37 | 111.69 |
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
Vaxcyte (NAS:PCVX) Shares Outstanding (Basic Average) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Be Aware
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Thank you for viewing the detailed overview of Vaxcyte's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew Guggenhime | officer: CFO, CBO | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
Grant Pickering | director, officer: President & CEO | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
Mikhail Eydelman | officer: SVP, Gen Counsel & Corp Sec | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070 |
Jim Wassil | officer: Chief Operating Officer | C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404 |
Heath Lukatch | director | 326 BOLLAY DRIVE, GOLETA CA 93117 |
Elvia Cowan | officer: See Remarks Section | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070 |
Jeff Fairman | officer: VP, Research | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
Paul Sauer | officer: SVP Process Dev, Manufacturing | C/O VAXCYTE, INC., 825 INDUSTRIAL DRIVE, STE. 300, SAN CARLOS CA 94404 |
Michael E. Kamarck | director | C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406 |
Carlos V Paya | director | C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102 |
Harpreet S. Dhaliwal | officer: SVP Cml Mfg & Supply Chain | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
Anne S Drapeau | director | C/O IRON MOUNTAIN INCORPORATED, ONE FEDERAL STREET, BOSTON MA 02110 |
Teri Loxam | director | C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472 |
Jane Wright Mitchell | officer: General Counsel | C/0 ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
Robert Lorne Hopfner | director | C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111 |
From GuruFocus
By Marketwired • 10-19-2023
By GlobeNewswire GlobeNewswire • 04-21-2023
By Value_Insider Value_Insider • 11-07-2022
By sperokesalga sperokesalga • 04-17-2023
By GuruFocus Research • 11-23-2023
By sperokesalga sperokesalga • 05-03-2023
By sperokesalga sperokesalga • 06-01-2023
By Stock market mentor Stock market mentor • 02-07-2023
By GuruFocus Research • 11-06-2023
By GuruFocus Research • 01-20-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.